# KEYNOTE-641 (NCT03834493)

> Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab plus enzalutamide
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03834493
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Prostatic Neoplasms
- Interventions: Pembrolizumab; Enzalutamide; Placebo
- Enrollment: 1244
- Primary outcome: Overall Survival (OS)
- Primary outcome: Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review

## Indexed commentary on KEYNOTE-641 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keynote-641-nct03834493